Quang Duy Pham1, Nhan Thi Do2, Yen Ngoc Le3, Thuong Vu Nguyen4, Duc Bui Nguyen3, Thu Khanh Hoang Huynh5, Duong Duc Bui2, Nghia Van Khuu4, Phuc Duy Nguyen4, Anh Que Luong5, Hien Thu Bui3, Hai Huu Nguyen2, Michelle McConnell3, Long Thanh Nguyen6, Lei Zhang7, Lien Xuan Truong8. 1. Department for Disease Control and Prevention, Pasteur Institute, Ho Chi Minh City, Vietnam Surveillannce and Evaluation Program for Public Health, Kirby Institute, UNSW Australia, Sydney, NSW, Australia. 2. Department of HIV Care and Treatment, Vietnam Authority of HIV/AIDS Control, Hanoi, Vietnam. 3. U.S. Centers for Disease Control and Prevention, Hanoi, Vietnam. 4. Department for Disease Control and Prevention, Pasteur Institute, Ho Chi Minh City, Vietnam. 5. Department of Laboratory Analysis, Pasteur Institute, Ho Chi Minh City, Vietnam. 6. Ministry of Health, Hanoi, Vietnam. 7. Surveillannce and Evaluation Program for Public Health, Kirby Institute, UNSW Australia, Sydney, NSW, Australia. 8. Department of Laboratory Analysis, Pasteur Institute, Ho Chi Minh City, Vietnam truongxuanlien@gmail.com.
Abstract
OBJECTIVES: The objective of this study was to determine the prevalence and correlates of pretreatment drug resistance (PDR) to first-line antiretroviral drugs among people initiating therapy for HIV in Vietnam. METHODS: Blood was collected during November 2009 to October 2010 from people consecutively initiating ART in four purposively selected public outpatient clinics in three Vietnamese cities. At each study site, recruitment lasted for 6-10 months until the target sample size (range 120-130 individuals) had been reached. The viral load was measured in 501 samples; 490 samples (viral load ≥1000 copies/mL) were genotyped using a nucleotide population-based sequencing assay. Self-reported demographic and clinical data were elicited through interviews. We classified drug-resistance-associated mutations (DRMs) according to the 2009 WHO surveillance list. RESULTS: DRMs were identified in 17/490 participants (3.5%; 95% CI 2.2%-5.5%). The prevalence of DRMs was 1.6% (8/490) against NRTIs, 1.6% (8/490) against NNRTIs and 0.8% (4/490) against PIs; three (0.6%) participants were resistant to both NRTIs and NNRTIs. The overall prevalence of PDR to first-line drugs was low [2.7% (13/490); 95% CI 1.6%-4.4%]. The prevalence of PDR to first-line drugs was greater among 198 HIV-infected participants who injected drugs than among 286 participants who reported risks for sexually acquired HIV (4.0% versus 1.4%, P = 0.079). Multivariable logistic regression analysis suggested that PDR to first-line drugs was significantly higher among people who injected drugs (OR = 3.94; 95% CI 1.13-13.68). CONCLUSIONS: With low PDR, first-line ART may be effective in Vietnam and pretreatment genotyping may be unnecessary. Continuing strategies for the prevention and surveillance of antiretroviral resistance are important for maintaining a low prevalence of antiretroviral resistance in Vietnam. The association between resistance and injection drug use warrants further research.
OBJECTIVES: The objective of this study was to determine the prevalence and correlates of pretreatment drug resistance (PDR) to first-line antiretroviral drugs among people initiating therapy for HIV in Vietnam. METHODS: Blood was collected during November 2009 to October 2010 from people consecutively initiating ART in four purposively selected public outpatient clinics in three Vietnamese cities. At each study site, recruitment lasted for 6-10 months until the target sample size (range 120-130 individuals) had been reached. The viral load was measured in 501 samples; 490 samples (viral load ≥1000 copies/mL) were genotyped using a nucleotide population-based sequencing assay. Self-reported demographic and clinical data were elicited through interviews. We classified drug-resistance-associated mutations (DRMs) according to the 2009 WHO surveillance list. RESULTS: DRMs were identified in 17/490 participants (3.5%; 95% CI 2.2%-5.5%). The prevalence of DRMs was 1.6% (8/490) against NRTIs, 1.6% (8/490) against NNRTIs and 0.8% (4/490) against PIs; three (0.6%) participants were resistant to both NRTIs and NNRTIs. The overall prevalence of PDR to first-line drugs was low [2.7% (13/490); 95% CI 1.6%-4.4%]. The prevalence of PDR to first-line drugs was greater among 198 HIV-infectedparticipants who injected drugs than among 286 participants who reported risks for sexually acquired HIV (4.0% versus 1.4%, P = 0.079). Multivariable logistic regression analysis suggested that PDR to first-line drugs was significantly higher among people who injected drugs (OR = 3.94; 95% CI 1.13-13.68). CONCLUSIONS: With low PDR, first-line ART may be effective in Vietnam and pretreatment genotyping may be unnecessary. Continuing strategies for the prevention and surveillance of antiretroviral resistance are important for maintaining a low prevalence of antiretroviral resistance in Vietnam. The association between resistance and injection drug use warrants further research.
Authors: Silvia Bertagnolio; Andrea De Luca; Marco Vitoria; Shaffiq Essajee; Martina Penazzato; Steven Y Hong; Craig McClure; Chris Duncombe; Michael R Jordan Journal: Antivir Ther Date: 2012-08-16
Authors: Linda Wittkop; Huldrych F Günthard; Frank de Wolf; David Dunn; Alessandro Cozzi-Lepri; Andrea de Luca; Claudia Kücherer; Niels Obel; Viktor von Wyl; Bernard Masquelier; Christoph Stephan; Carlo Torti; Andrea Antinori; Federico García; Ali Judd; Kholoud Porter; Rodolphe Thiébaut; Hannah Castro; Ard I van Sighem; Céline Colin; Jesper Kjaer; Jens D Lundgren; Roger Paredes; Anton Pozniak; Bonaventura Clotet; Andrew Phillips; Deenan Pillay; Geneviève Chêne Journal: Lancet Infect Dis Date: 2011-02-25 Impact factor: 25.071
Authors: Diane E Bennett; Ricardo J Camacho; Dan Otelea; Daniel R Kuritzkes; Hervé Fleury; Mark Kiuchi; Walid Heneine; Rami Kantor; Michael R Jordan; Jonathan M Schapiro; Anne-Mieke Vandamme; Paul Sandstrom; Charles A B Boucher; David van de Vijver; Soo-Yon Rhee; Tommy F Liu; Deenan Pillay; Robert W Shafer Journal: PLoS One Date: 2009-03-06 Impact factor: 3.240
Authors: Philip J Palumbo; Yinfeng Zhang; Jessica M Fogel; Xu Guo; William Clarke; Autumn Breaud; Paul Richardson; Estelle Piwowar-Manning; Stephen Hart; Erica L Hamilton; Ngo T K Hoa; Mariya Liulchuk; Latifah Anandari; Tran Viet Ha; Kostyantyn Dumchev; Zubairi Djoerban; Irving Hoffman; Brett Hanscom; William C Miller; Susan H Eshleman Journal: PLoS One Date: 2019-10-10 Impact factor: 3.240